Literature DB >> 19763115

Predicting age-specific dosing of antipsychotics.

H Uchida1, B G Pollock, R R Bies, D C Mamo.   

Abstract

Antipsychotic medications are the standard of care for both acute and maintenance treatment of schizophrenia, the latter requiring an indefinite treatment across a patient's life span. However, dosing and tolerability of antipsychotics have been studied primarily in younger patients, and very limited data are available for age- and phase-specific dosing. This leaves the clinician with no guidance on dose adjustment as patients grow older-an issue of critical importance, especially in light of recent concerns about increased morbidity and mortality associated with antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19763115     DOI: 10.1038/clpt.2009.133

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

Authors:  Shinichiro Nakajima; Hiroyuki Uchida; Robert R Bies; Fernando Caravaggio; Takefumi Suzuki; Eric Plitman; Wanna Mar; Philip Gerretsen; Bruce G Pollock; Benoit H Mulsant; David C Mamo; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

2.  Brain and disease: the long path to discovery and treatment.

Authors:  S L Miksys; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2009-10       Impact factor: 6.875

3.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

Review 4.  A tipping point in drug dosing in late-life schizophrenia.

Authors:  Takashi Tsuboi; Takefumi Suzuki; Hiroyuki Uchida
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

5.  Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

Review 6.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

7.  Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

Authors:  Hitoshi Sakurai; Robert R Bies; Scott T Stroup; Richard S E Keefe; Tarek K Rajji; Takefumi Suzuki; David C Mamo; Bruce G Pollock; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2012-01-30       Impact factor: 9.306

8.  Geriatric mental health: Recent trends in molecular neuroscience.

Authors:  T S Sathyanarayana Rao; B Praveena; K S Jagannatha Rao
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

9.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

10.  Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009.

Authors:  Yu-Tao Xiang; Robert W Buchanan; Gabor S Ungvari; Helen F K Chiu; Kelly Y C Lai; You-Hong Li; Tian-Mei Si; Chuan-Yue Wang; Edwin H M Lee; Yan-Ling He; Shu-Yu Yang; Mian-Yoon Chong; Ee-Heok Kua; Senta Fujii; Kang Sim; Michael K H Yong; Jitendra K Trivedi; Eun-Kee Chung; Pichet Udomratn; Kok-Yoon Chee; Norman Sartorius; Chay-Hoon Tan; Naotaka Shinfuku
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.